Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
DNA Ginkgo Bioworks Holdings, Inc.
Anna Attkisson is a full-time Senior Editorial Director for Investopedia, overseeing content strategy and operations. Anna has spent 20 years crafting content around highly complex topics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback